AstraZeneca: Earnings Beat Expectations, but the Crucial Test Is Still Ahead

The financial world took notice after AstraZeneca released its latest results and outlined the company’s future direction. Although investors’ initial reaction was positive, several questions remain beneath the surface that could influence the future performance of its stock. Attention is therefore focused not only on the past quarter but, above all, on whether the pharmaceutical giant can fulfill its ambitious plans. The coming months may reveal whether the market’s confidence is truly justified. [1]

About the company

AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, UK. The company was formed in 1999 through the merger of the Swedish firm Astra AB and the British company Zeneca Group PLC. It is engaged in the research, development, manufacture, and sale of prescription drugs. Its main areas of focus include oncology, chronic diseases, respiratory diseases, immunology, and rare diseases. In 2025, it achieved total sales of $58.7 billion, had 16 drugs with annual sales exceeding $1 billion, and had 197 projects in its development portfolio. By 2030, it plans to launch at least 20 new drugs and increase annual revenue to $80 billion.[1]2 [2]

Earnings exceeded expectations

AstraZeneca reported total revenue of $15.38 billion in the second quarter of 2026, representing year-over-year growth of 6% at current exchange rates and 5% at constant exchange rates. The result was virtually in line with analysts’ expectations of $15.39 billion. Adjusted earnings per share came as a much bigger surprise, reaching $2.63 and beating the consensus estimate of $2.48. Year-over-year, they increased by 21%, while excluding currency effects, they rose by 18%. Adjusted operating profit reached $5.16 billion, and its 10% growth outpaced the pace of revenue growth. At the same time, the gross margin increased by 1 percentage point to 84%. However, a lower tax rate of 15% also contributed to the profit growth, so it will not be easy to maintain the same pace in future periods. For the first half of the year, AstraZeneca generated revenue of $30.67 billion and adjusted earnings of $5.21 per share, confirming continued growth despite pressure on several older drugs.[2] *

Oncology remains the main driver

Oncology remained the most important pillar of the results, generating revenue of $7.33 billion in the second quarter and accounting for approximately 48% of the company’s total revenue. Segment revenue grew by 15% at constant exchange rates, offsetting the weaker performance of several older drugs. Sales of Tagrisso reached $1.94 billion, up 6% year-over-year. Imfinzi posted even stronger growth, with sales jumping 27% to $1.85 billion. Calquence rose 16% to $1.02 billion, and AstraZeneca increased sales of Enhertu by 44% to $338 million. It generated an additional $550 million through alliance revenues related to this drug. The rare diseases segment also posted strong performance, with sales rising 8% to $2.49 billion. Ultomiris generated $1.31 billion, and Strensiq increased sales by 36% to $536 million. The company’s growth thus continues to be driven primarily by newer oncology drugs and the portfolio acquired through the acquisition of Alexion.2

Farxiga and China reveal weaknesses

Strong growth in oncology masked a significant decline in the cardiovascular, renal, and metabolic segment, whose revenue fell by 18% to $2.77 billion at constant exchange rates. The biggest negative impact came from Farxiga, whose quarterly sales fell by 19% to $1.80 billion. In the United States, its sales plummeted by 48% to $219 million following the entry of several generic competitors into the market. China, the company’s second-largest market, also remained a weak spot. Revenue in the country fell by 13% at constant exchange rates to $1.59 billion, accounting for approximately 10% of total revenue. This was due to growing generic competition and changes in the government’s bulk drug procurement system. Developments in other regions were significantly more favorable. Sales in the United States rose by 6% to $6.69 billion, European revenue increased by 7% to $3.42 billion, and emerging markets excluding China recorded growth of 11% to $2.33 billion.2

Growth requires increasing amounts of capital

Despite rising revenue, cash generation weakened during the first half of the year. Net cash flow from operating activities fell from $7.10 billion to $6.22 billion, representing a year-over-year decrease of $875 million. This was negatively impacted by a $1.44 billion change in working capital and higher taxes paid, which rose from $1.55 billion to $2.05 billion. Capital expenditures increased by $210 million to $1.51 billion, as AstraZeneca continued to invest in manufacturing facilities and technology infrastructure. Cash outflows from investing activities totaled $4.70 billion and included a $1.10 billion payment to CSPC Pharmaceuticals for rights to new drug projects. As a result, net debt increased by $3.54 billion from the end of 2025 to $26.91 billion. Despite this, AstraZeneca increased its interim dividend by 3 cents to $1.06 per share. The company thus continues to reward shareholders while simultaneously allocating a larger portion of its resources to drug development, the acquisition of rights, and the expansion of manufacturing capacity.2

The decisive eighteen months

AstraZeneca has left its outlook for 2026 unchanged. Total revenue is expected to grow by a mid- to high-single-digit percentage at constant exchange rates, and adjusted earnings per share are projected to grow by a low double-digit percentage. The company also continues to expect to reach annual revenue of $80 billion by 2030. However, achieving this goal will not depend solely on its current drugs. Over the next 18 months, AstraZeneca faces more than 20 key Phase 3 clinical trial results that could either confirm or undermine the value of its development portfolio. The risk was highlighted by the recent failure of the Wainua drug trial, following which the company lost approximately $20 billion in market value. On the other hand, management raised its estimate for the peak annual sales of the upcoming respiratory drug tozorakimab from more than $3 billion to more than $5 billion. Shares rose by approximately 1.7% following the earnings announcement but remained down about 7% year-to-date. The second-quarter results confirmed the strength of the company’s current business, but the future performance of the stock will be determined primarily by the success of clinical trials and the ability of new drugs to replace revenue from products losing patent protection.2[3] [3]

AstraZeneca’s stock price performance over the past five years*

Conclusion

AstraZeneca now stands at a point where its future growth will depend not only on strong results in oncology, but primarily on the success of new drugs and upcoming clinical trials. The combination of a growing portfolio, more than 20 anticipated Phase 3 trial results, expansion into rare diseases, and the ambition to reach $80 billion in revenue by 2030 creates significant room for further growth. Risks include a decline in sales of older products, weaker performance in China, and the stock’s high sensitivity to the results of individual clinical trials. If AstraZeneca can successfully bring new therapies to market, replace declining revenue from older drugs, and maintain its current pace of profitability growth, its second-quarter 2026 results may be just the beginning of the next major phase of its development.2 [4]

[1,2,3,4] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate, or on the current economic environment, which is subject to change. Such statements are not a guarantee of future performance. They involve risks and other uncertainties that are difficult to predict. Actual results may differ materially from those expressed or implied in any forward-looking statements.

* Past performance is no guarantee of future returns.

O.Z.I. Online Zone Investment Opportunities (OZIOS) is a registered trademark of APME FX TRADING EUROPE LTD, a Cyprus Investment Firm (CIF) supervised and regulated by the Cyprus Securities and Exchange Commission (CySEC) under CIF license number 335/17, with a registered address at Lophitis Business Center, Office 404, 4th Floor, 28 October Ave 249, Limassol 3035, Cyprus. Contracts for Difference (CFDs) are complex instruments and carry a high risk of rapid financial loss due to leverage. 81.54% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

[1] https://en.wikipedia.org/wiki/AstraZeneca

[2] https://www.astrazeneca.com/investor-relations/h1-and-q2-2026-results-event.html

[3] https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-beats-second-quarter-profit-expectations-holds-outlook-2026-07-27/